Name: A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic
Uploaded: 2020-05-17T04:00:01Z
Description: A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.

As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority  

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma. 

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Premal Thaker, MD, MS, discusses how the RAMP-201 trial paved a way for the RAMP-301 trial of avutometinib/defactinib in low-grade serous ovarian cancer.

Avutometinib Plus Defactinib Makes a Phase 3 Debut in Low-Grade Serous Ovarian Cancer

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

Revisit Every OncLive On Air Episode from March 2024

The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.

Quality Over Quantity: What Concierge Medicine Can Offer to Patients With Cancer and Employers

Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.

First-Line Pembrolizumab Plus Chemo Wins Canadian Approval for HER2– Advanced Gastric/GEJ Adenocarcinoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

Videos

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. We will feature a panel of experts from the nation’s leading cancer centers, led by Eric P. Winer, MD, to discuss important topics and key information for treating patients with breast cancer.

Regional differences in the management of patients with breast cancer during the COVID-19 pandemic

Institutional best practices for treating patients with breast cancer that have the novel coronavirus or who may be at risk for developing it

Guidelines on the prioritization and management of patients with breast cancer

Professor, Medicine, Harvard Medical School

Director, Breast Oncology Center, Dana-Farber Cancer Institute

Physician Active Staff, Medicine, Brigham And Women's Hospital

Thompson Chair, Breast Cancer Research, Dana-Farber Cancer Institute

Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research

Chief of the Division of Oncology, Stanford University Medical Center

Chief, Breast Service, Department of Surgery

Anne Burnett Windfohr Chair of Clinical Oncology

Professor of Surgery, Weill Cornell Medical College

 : Novartis / In association with Dana Farber

A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

Latest Conference Coverage